Prognostic impact of body mass index (BMI) in HER2+ breast cancer treated with anti-HER2 therapies: from preclinical rationale to clinical implications
Human Epidermal growth factor Receptor 2 (HER2) overexpression or HER2 gene amplification defines a subset of breast cancers (BCs) characterized by higher biological and clinical aggressiveness. The introduction of anti-HER2 drugs has remarkably improved clinical outcomes in patients with both early...
Gardado en:
| Principais autores: | , , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
SAGE Publishing
2022-03-01
|
| Series: | Therapeutic Advances in Medical Oncology |
| Acceso en liña: | https://doi.org/10.1177/17588359221079123 |
| Tags: |
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|